Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common stock, $0.0001 par value
-
Shares outstanding
-
49.9M
-
Number of holders
-
54
-
Total 13F shares, excl. options
-
9.56M
-
Shares change
-
+1.09M
-
Total reported value, excl. options
-
$44.5M
-
Value change
-
+$5.04M
-
Number of buys
-
27
-
Number of sells
-
-13
-
Price
-
$4.65
Significant Holders of TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) as of Q3 2025
56 filings reported holding TLSI - TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value as of Q3 2025.
TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) has 54 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.56M shares
of 49.9M outstanding shares and own 19.17% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (2.04M shares), AWM Investment Company, Inc. (1.25M shares), VANGUARD GROUP INC (1.16M shares), GILDER GAGNON HOWE & CO LLC (1.05M shares), BlackRock, Inc. (788K shares), Wealthcare Advisory Partners LLC (644K shares), Alyeska Investment Group, L.P. (558K shares), GEODE CAPITAL MANAGEMENT, LLC (554K shares), STATE STREET CORP (193K shares), and BANK OF AMERICA CORP /DE/ (189K shares).
This table shows the top 54 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.